AU772478B2 - Phosphoramidate, and mono-, DI-, and tri-phosphate esters of (1R,CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentene-1- methanol as antiviral agents - Google Patents

Phosphoramidate, and mono-, DI-, and tri-phosphate esters of (1R,CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentene-1- methanol as antiviral agents Download PDF

Info

Publication number
AU772478B2
AU772478B2 AU26713/00A AU2671300A AU772478B2 AU 772478 B2 AU772478 B2 AU 772478B2 AU 26713/00 A AU26713/00 A AU 26713/00A AU 2671300 A AU2671300 A AU 2671300A AU 772478 B2 AU772478 B2 AU 772478B2
Authority
AU
Australia
Prior art keywords
methanol
cis
amino
cyclopentene
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26713/00A
Other languages
English (en)
Other versions
AU2671300A (en
Inventor
Susan Mary Daluge
Christopher Mcguigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Glaxo Group Ltd
Original Assignee
University College Cardiff Consultants Ltd
Glaxo Group Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903090.0A external-priority patent/GB9903090D0/en
Application filed by University College Cardiff Consultants Ltd, Glaxo Group Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Publication of AU2671300A publication Critical patent/AU2671300A/en
Application granted granted Critical
Publication of AU772478B2 publication Critical patent/AU772478B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU26713/00A 1999-02-12 2000-02-10 Phosphoramidate, and mono-, DI-, and tri-phosphate esters of (1R,CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentene-1- methanol as antiviral agents Ceased AU772478B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9903090.0A GB9903090D0 (en) 1999-02-12 1999-02-12 Therapeutic compounds
GB9903090 1999-02-12
US17020599P 1999-12-10 1999-12-10
US60/170205 1999-12-10
PCT/EP2000/001045 WO2000047591A1 (en) 1999-02-12 2000-02-10 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents

Publications (2)

Publication Number Publication Date
AU2671300A AU2671300A (en) 2000-08-29
AU772478B2 true AU772478B2 (en) 2004-04-29

Family

ID=26315118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26713/00A Ceased AU772478B2 (en) 1999-02-12 2000-02-10 Phosphoramidate, and mono-, DI-, and tri-phosphate esters of (1R,CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentene-1- methanol as antiviral agents

Country Status (24)

Country Link
US (1) US7115590B1 (enExample)
EP (1) EP1150988B1 (enExample)
JP (1) JP2002536452A (enExample)
KR (1) KR20010102082A (enExample)
CN (1) CN1346360A (enExample)
AR (1) AR031975A1 (enExample)
AT (1) ATE241633T1 (enExample)
AU (1) AU772478B2 (enExample)
BR (1) BR0008135A (enExample)
CA (1) CA2362662A1 (enExample)
CZ (1) CZ20012908A3 (enExample)
DE (1) DE60002986T2 (enExample)
DK (1) DK1150988T3 (enExample)
DZ (1) DZ3007A1 (enExample)
ES (1) ES2200820T3 (enExample)
HK (1) HK1039337B (enExample)
HU (1) HUP0105476A3 (enExample)
IL (1) IL144647A0 (enExample)
NO (1) NO20013910L (enExample)
NZ (1) NZ513450A (enExample)
PL (1) PL204458B1 (enExample)
PT (1) PT1150988E (enExample)
TR (1) TR200102313T2 (enExample)
WO (1) WO2000047591A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
JP2003516408A (ja) * 1999-12-10 2003-05-13 グラクソ グループ リミテッド 抗ウィルス薬としての（１Ｒ，シス）−４−［４−アミノ−７Ｈ−ピロロ（２，３−ｄ）ピリミジン−７−イル］−２−シクロペンテン−１−メタノール類縁物
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
HRP20030047B1 (hr) † 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
GB0129945D0 (en) * 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions
WO2026151964A1 (en) 2025-01-10 2026-07-16 Atea Pharmaceuticals, Inc. Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6887707B2 (en) * 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP2003516408A (ja) * 1999-12-10 2003-05-13 グラクソ グループ リミテッド 抗ウィルス薬としての（１Ｒ，シス）−４−［４−アミノ−７Ｈ−ピロロ（２，３−ｄ）ピリミジン−７−イル］−２−シクロペンテン−１−メタノール類縁物
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof

Also Published As

Publication number Publication date
US7115590B1 (en) 2006-10-03
PL204458B1 (pl) 2010-01-29
NZ513450A (en) 2004-03-26
DK1150988T3 (da) 2003-09-29
NO20013910L (no) 2001-10-10
DE60002986D1 (en) 2003-07-03
ATE241633T1 (de) 2003-06-15
WO2000047591A1 (en) 2000-08-17
BR0008135A (pt) 2002-02-19
KR20010102082A (ko) 2001-11-15
IL144647A0 (en) 2002-05-23
NO20013910D0 (no) 2001-08-10
PT1150988E (pt) 2003-10-31
HUP0105476A2 (en) 2002-06-29
TR200102313T2 (tr) 2002-03-21
EP1150988B1 (en) 2003-05-28
CZ20012908A3 (cs) 2002-10-16
EP1150988A1 (en) 2001-11-07
HUP0105476A3 (en) 2002-08-28
DZ3007A1 (fr) 2003-03-27
ES2200820T3 (es) 2004-03-16
AU2671300A (en) 2000-08-29
HK1039337B (en) 2003-11-21
CA2362662A1 (en) 2000-08-17
JP2002536452A (ja) 2002-10-29
PL350023A1 (en) 2002-10-21
AR031975A1 (es) 2003-10-22
HK1039337A1 (en) 2002-04-19
DE60002986T2 (de) 2004-05-19
CN1346360A (zh) 2002-04-24

Similar Documents

Publication Publication Date Title
EP1150988B1 (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
AU2023200990B2 (en) Methods for treating Arenaviridae and Coronaviridae virus infections
AU2022283772A1 (en) Methods for treating Filoviridae virus infections
AU2004233898B2 (en) Antiviral phosphonate analogs
DE60315023T2 (de) Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
EP1742642B1 (en) Phosphonate analogs of hiv integrase inhibitor compounds
MX2007001053A (es) Analogos de fosfonato de compuestos inhibidores de vih.
KR20020093824A (ko) 포스포네이트 뉴클레오티드 화합물
AU2004260789B2 (en) Nucleobase phosphonate analogs for antiviral treatment
AU2013349750A1 (en) Phosphonucleosides useful in the treatment of viral disorders
US20030045508A1 (en) (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
EP1235833B1 (en) Analogs of (1s, cis)-4-(2-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral
US20030040506A1 (en) Analogs of (1s,cis)-4-(2-amino-9h-purin -9-yl) -2-Cyclopentene-1-methanol as antiviral
MXPA01008129A (es) Esteres de fosforamidato, y mono-, di-, y tri-fosfato de (1r, cis)-4-(6-amino-9h-purin-9-il)-2- ciclopenteno-1-metanol como agentes antivirales.
AU2011224011A1 (en) Phosphonate analogs of HIV inhibitor compounds
HK1103649B (en) Nucleoside phosphonate conjugates as anti hiv agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)